Skip to content

CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)

Cancer | Cancer, Therapy-Related | Malignant Solid Tumor | Malignancies Multiple | Molecular Sequence...

This study will collect data on Canadian cancer patients that have uncommon/rare changes in their tumours, such as alterations/rearrangements in the genetic material inside cells - known as deoxyribonucleic acid, or DNA, which acts as a map and gives directions to the cells on how to make other substances the body needs - because some of these changes have been found to respond to different drugs that help to stop the cancer. These rare changes occur in genes such as but not limited to ALK, EGFR, ROS1, BRAF, and NTRK which have targeted drugs in a family known as tyrosine kinase inhibitors (TKIs), and KRAS G12C mutation, which now has a targeted inhibitor drug therapy for patients with non small cell lung cancer (NSCLC). The goals for the study are to compare the natural history of such cancers and the treatment outcomes, including toxicities and patient-reported outcomes, for the different therapies.

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

* Patients ≥ 18 years at cancer diagnosis
* Diagnosed with malignant tumour(s) with molecular testing completed that identified rare molecular alterations
* Accessible/available molecular testing reports/documentation to confirm type(s) of molecular alteration(s) (resulting from the conduct of polymerase chain reaction \[PCR\] based next generation sequencing \[NGS\], immunohistochemistry \[IHC\], fluorescence in situ hybridization \[FISH\], liquid biopsy)
* Canadian resident received follow-up for cancer care in Canada or is currently receiving/planning follow-up for cancer care to occur in Canada at time of enrollment

Exclusion Criteria:

* Previous refusal of the deceased patient, when living, to enroll in this study or patient approached for this study is unable to provide informed consent

Study Location

Tom Baker Cancer Centre - University of Calgary - Alberta Health Services
Tom Baker Cancer Centre - University of Calgary - Alberta Health Services
Calgary, Alberta
Canada

Contact Study Team

Primary Contact

Roula Raptis, MSc

[email protected]
Dr. Everett Chalmers Regional Hospital
Dr. Everett Chalmers Regional Hospital
Fredericton, New Brunswick
Canada

Contact Study Team

Primary Contact

Roula Raptis, MSc

[email protected]
Hamilton Health Sciences - Juravinski Cancer Centre
Hamilton Health Sciences - Juravinski Cancer Centre
Hamilton, Ontario
Canada

Contact Study Team

Primary Contact

Roula Raptis, MSc

[email protected]
Health Sciences North
Health Sciences North
Sudbury, Ontario
Canada

Contact Study Team

Primary Contact

Roula Raptis, MSc

[email protected]
Sunnybrook Research Institute - Sunnybrook Health Sciences Centre
Sunnybrook Research Institute - Sunnybrook Health Sciences Centre
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Roula Raptis, MSc

[email protected]
McGill University Health Centre
McGill University Health Centre
Montréal, Quebec
Canada

Contact Study Team

Primary Contact

Roula Raptis, MSc

[email protected]
Centre hospitalier universitaire de Sherbrooke (CHUS)
Centre hospitalier universitaire de Sherbrooke (CHUS)
Sherbrooke, Quebec
Canada

Contact Study Team

Primary Contact

Roula Raptis, MSc

[email protected]
CancerCare Manitoba/University of Manitoba
CancerCare Manitoba/University of Manitoba
Winnipeg, Manitoba
Canada

Contact Study Team

Primary Contact

Roula Raptis, MSc

[email protected]
William Osler Health System - Brampton Civic Hospital
William Osler Health System - Brampton Civic Hospital
Brampton, Ontario
Canada

Contact Study Team

Primary Contact

Roula Raptis, MSc

[email protected]
Ottawa Hospital Cancer Centre
Ottawa Hospital Cancer Centre
Ottawa, Ontario
Canada

Contact Study Team

Primary Contact

Roula Raptis, MSc

[email protected]
Mount Sinai Hospital
Mount Sinai Hospital
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Roula Raptis, MSc

[email protected]
Jewish General Hospital
Jewish General Hospital
Montréal, Quebec
Canada

Contact Study Team

Primary Contact

Roula Raptis, MSc

[email protected]
Institut Universitaire de Cardiologie et de Pneumologie de Québec
Institut Universitaire de Cardiologie et de Pneumologie de Québec
Québec City, Quebec
Canada

Contact Study Team

Primary Contact

Roula Raptis, MSc

[email protected]
Cross Cancer Institute, University of Alberta - Alberta Health Services
Cross Cancer Institute, University of Alberta - Alberta Health Services
Edmonton, Alberta
Canada

Contact Study Team

Primary Contact

Roula Raptis, MSc

[email protected]
Dr. H. Bliss Murphy Cancer Centre
Dr. H. Bliss Murphy Cancer Centre
Saint John's, Newfoundland and Labrador
Canada

Contact Study Team

Primary Contact

Roula Raptis, MSc

[email protected]
Kingston Health Sciences Centre (KHSC)
Kingston Health Sciences Centre (KHSC)
Kingston, Ontario
Canada

Contact Study Team

Primary Contact

Roula Raptis, MSc

[email protected]
Thunder Bay Regional Health Sciences Centre
Thunder Bay Regional Health Sciences Centre
Thunder Bay, Ontario
Canada

Contact Study Team

Primary Contact

Roula Raptis, MSc

[email protected]
Centre hospitalier de l'Université de Montréal (CHUM)
Centre hospitalier de l'Université de Montréal (CHUM)
Montréal, Quebec
Canada

Contact Study Team

Primary Contact

Roula Raptis, MSc

[email protected]
St. Mary's Hospital Center
St. Mary's Hospital Center
Montréal, Quebec
Canada

Contact Study Team

Primary Contact

Roula Raptis, MSc

[email protected]
Allan Blair Cancer Centre
Allan Blair Cancer Centre
Regina, Saskatchewan
Canada

Contact Study Team

Primary Contact

Roula Raptis, MSc

[email protected]
BC Cancer
BC Cancer
Vancouver, British Columbia
Canada

Contact Study Team

Primary Contact

Roula Raptis, MSc

[email protected]
Queen Elizabeth II (QEII) Health Sciences Centre
Queen Elizabeth II (QEII) Health Sciences Centre
Halifax, Nova Scotia
Canada

Contact Study Team

Primary Contact

Roula Raptis, MSc

[email protected]
Lawson Health Research Institute - London Health Sciences Centre
Lawson Health Research Institute - London Health Sciences Centre
London, Ontario
Canada

Contact Study Team

Primary Contact

Roula Raptis, MSc

[email protected]
Princess Margaret Cancer Centre (PMCC) - University Health Network (UHN)
Princess Margaret Cancer Centre (PMCC) - University Health Network (UHN)
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Devalben Patel, BSc, MLT

[email protected]
416-581-7447
Hôpital du Sacré-Coeur-de-Montréal (HSCM)
Hôpital du Sacré-Coeur-de-Montréal (HSCM)
Montréal, Quebec
Canada

Contact Study Team

Primary Contact

Roula Raptis, MSc

[email protected]
Centre hospitalier de l'université de Québec - Université Laval
Centre hospitalier de l'université de Québec - Université Laval
Québec City, Quebec
Canada

Contact Study Team

Primary Contact

Roula Raptis, MSc

[email protected]
Saskatoon Cancer Centre
Saskatoon Cancer Centre
Saskatoon, Saskatchewan
Canada

Contact Study Team

Primary Contact

Roula Raptis, MSc

[email protected]
Study Sponsored By
University Health Network, Toronto
Participants Required
More Information
Study ID: NCT04151342